Cochrane Evidence Synthesis and Methods ►

3,4-Diaminopyridine for myasthenia gravis

To assess the benefits and harms of 3,4-DAP for autoimmune MG, transient NMG and the CMS on 1) endurance, and 2) muscle strength, quality of life and Myasthenia Gravis Foundation of America (MGFA) status.

This is a protocol.

Health topics:

Cancer > Neurological > Paraneoplastic syndromes

Genetic disorders > Other genetic disorders

Neurology > Neuro-oncology > Paraneoplastic syndromes

Neurology > Neuromuscular junction disorders > Myasthenia gravis

Neurology > Peripheral neuropathy > Myasthenia gravis

Published:

15 February 2012

Authors:

Vrinten C, Weinreich SS., Scholten RJPM, Verschuuren JJGM

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Vrinten C, Weinreich SS., Scholten RJPM, Verschuuren JJGM. 3,4-Diaminopyridine for myasthenia gravis. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD009675. DOI: 10.1002/14651858.CD009675